Skip to main navigation Skip to search Skip to main content

Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: Retrospective analysis from a single center

  • Sook Hee Hong
  • , Yu Ri Shin
  • , Sang Young Roh
  • , Eun Kyoung Jeon
  • , Kyo Yung Song
  • , Cho Hyun Park
  • , Hae Myung Jeon
  • , Young Seon Hong
  • Catholic Univ. of Korea Coll. Med.
  • The Catholic University of Korea Incheon St. Mary's Hospital

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Abstract

Background: Few studies of systemic chemotherapy have focused on gastric cancer with peritoneal carcinomatosis (PC) without measurable lesions. In the present study, we characterized the outcomes of systemic chemotherapy and prognostic factors for gastric cancer with PC, particularly in patients without measurable disease. Methods: Clinical data from 211 gastric cancer patients with PC (137 without and 74 with measurable disease) who had received systemic chemotherapy between January 2003 and December 2010 at a single center were reviewed. Results: The median overall survival (OS) rate of gastric cancer patients with PC with no measurable disease was significantly longer than that of patients with measurable disease (18.0 vs. 11.6 months, p = 0.010). On multivariate analysis, poor performance status [hazard ratio (HR) = 2.15, p < 0.001], the presence of metastatic lymphadenopathy (HR = 2.17, p < 0.001), and high-grade PC (HR = 1.83, p = 0.001) were associated with significantly decreased OS. When patients with low-grade PC were stratified by clinical PC grade, the median OS of those without measurable disease was 19.6 months. The median OS of patients with low-grade PC with no measurable disease was longer than those of patients with high-grade PC without measurable disease, patients with low-grade PC with measurable disease, and patients with high-grade PC with measurable disease (p = 0.001, p = 0.029, and p < 0.001, respectively). Among the patients with low-grade PC, patients who received a gastrectomy had longer survival than patients who did not receive a gastrectomy (p < 0.001). Conclusions: In our study, clinically low-grade PC without measurable disease was associated with better outcomes of systemic chemotherapy than the outcomes in the other groups examined. Clinical trials in patients with gastric cancer with PC should be stratified according to PC grade.

Original languageEnglish
Pages (from-to)290-300
Number of pages11
JournalGastric Cancer
Volume16
Issue number3
DOIs
StatePublished - Jul 2013

Bibliographical note

Funding Information:
This research was supported by Seoul St. Mary’s Clinical Medicine Research Program year of 2009 through the Catholic University of Korea.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Gastric cancer
  • Measurable disease
  • Peritoneal carcinomatosis
  • Systemic chemotherapy

Fingerprint

Dive into the research topics of 'Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: Retrospective analysis from a single center'. Together they form a unique fingerprint.

Cite this